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The chief and largely terminal element of normal blood clotting is considered to involve the polymeri-
sation of the mainly a-helical ﬁbrinogen to ﬁbrin, with a binding mechanism involving ‘knobs and holes’
but with otherwise little change in protein secondary structure. We recognise, however, that extremely
unusual mutations or mechanical stressing can cause ﬁbrinogen to adopt a conformation containing
extensive b-sheets. Similarly, prions can change morphology from a largely a-helical to largely b-sheet
conformation, and the latter catalyses both the transition and the self-organising polymerisation of the
b-sheet structures. Many other proteins can also do this, where it is known as amyloidogenesis. When
ﬁbrin is formed in samples from patients harbouring different diseases it can have widely varying di-
ameters and morphologies. We here develop the idea, and summarise the evidence, that in many cases
the anomalous ﬁbrin ﬁbre formation seen in such diseases actually amounts to amyloidogenesis. In
particular, ﬁbrin can interact with the amyloid-b (Ab) protein that is misfolded in Alzheimer's disease.
Seeing these unusual ﬁbrin morphologies as true amyloids explains a great deal about ﬁbrin(ogen)
biology that was previously opaque, and provides novel strategies for treating such coagulopathies. The
literature on blood clotting can usefully both inform and be informed by that on prions and on the many
other widely recognised (b-)amyloid proteins. A preprint has been lodged in bioRxiv (Kell and Pretorius,
2016).
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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nolysis have seldom been discovered and characterized in
recent years” (Weisel, 2011)
1. Introduction: the thermodynamics of protein folding and
prion proteins, and the existence of multiple macrostates
Starting with Anﬁnsen's famous protein re-folding experiments
(Anﬁnsen, 1973; Anﬁnsen et al., 1961), showing that an unfolded
protein would refold reliably to its commonest (and original) state
as found in the cell, it was widely assumed that the normal mac-
rostate of a folded protein was that of its lowest free energy.
If one allows each amino acid to have n distinct conformational
substates, the total number nm scales exponentially with the
number m of amino acids (Kell, 2012), and until recently exhaustive
calculations to determine whether the ‘preferred’ conformation
was of lowest free energy were prohibitively expensive (Piana et al.,
2014, 2012, 2013; Verma and Wenzel, 2009); indeed, they still are
save for small proteins, so this question of whether the ‘normal’
conformation is that of lowest free energy (±kT) is certainly not
settled in general terms, and (as we shall see in many cases) formsFig. 1. PrPc conformation of human prion protein (1HJM at PDB).of lower free energy than the ‘normal’ one are in fact both common
and of high biological signiﬁcance.
In particular, as is again well known (Aguzzi and Calella, 2009;
Caughey et al., 2009; Colby and Prusiner, 2011; Prusiner, 1998), and
startingwith Virchow's observations in 1854 (Sipe and Cohen, 2000),
a number of proteins of a given sequence can exist in at least two (or
more) highly distinct conformations (e.g. (Chiti and Dobson, 2006;
Eisenberg and Jucker, 2012)). Typically the normal (‘benign’) form,
as produced initially within the cell, will have a signiﬁcant a-helical
content and a very low amount of b-sheet, but the abnormal (‘rogue’)
form, especially when in the form of an insoluble amyloid (Dobson,
2013), will have a massively increased amount of b-sheet (Baldwin
et al., 1994; Groveman et al., 2014; Harrison et al., 1997; Jack et al.,
2006; Jahn et al., 2008; Pan et al., 1993) (but cf (Ow and Dunstan,
2014)), whether parallel or antiparallel (Tycko and Wickner, 2013).
The canonical example is the prion protein PrPc, whose abnormal
form is known as PrPSc, andwhose PrPc structure is shown in Fig 1. As
is also well known, the monomers of the abnormal form may ca-
talyse their own formation from the normal form, and will typically
go on to self-assemble to form oligomers, protoﬁbrils and ﬁnally
insoluble ﬁbrils (Colby and Prusiner, 2011). (A particular hallmark of
PrPSc, and indeed a common basis for its assay, is its very great
resistance to proteolysis relative to PrPc, typically assessed using
proteinase K (Basu et al., 2007; Grassi et al., 2000;Mishra et al., 2004;
Saa and Cervenakova, 2015; Saleem et al., 2014; Saverioni et al., 2013;
Silva et al., 2015)).Fig. 2. Kinetic isolation of PrPSc from PrPC (based on (Cohen and Prusiner, 1998).
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conformational macrostate of such proteins is not in fact that of the
lowest free energy, and that its transition to the energetically more
favourable ‘rogue’ state is thermodynamically favourable but under
kinetic control, normally (in terms of transition state theory) with a
very high energy barrier DGy of maybe 36e38 kcal mol1 (Cohen
and Prusiner, 1998) (Fig 2). Certainly, for a given and more trac-
table model sequence such as poly-L-alanine (Henzler Wildman
et al., 2002), a b-sheet is demonstrably more stable than is an a-
helix. However, the reversibility by pressure in some cases implies
that the free energy change for oligomerisation is not particularly
great (Foguel et al., 2003). The formal deﬁnition (Sipe et al., 2014) of
an amyloid ﬁbril (protein) is as follows: “An amyloid ﬁbril protein is
a protein that is deposited as insoluble ﬁbrils, mainly in the
extracellular spaces of organs and tissues as a result of sequential
changes in protein folding that result in a condition known as
amyloidosis.”
Multiple states or conformations of amyloid/prion ‘strains’ are
sometimes referred to in this ﬁeld as ‘polymorphisms’ (Tycko,
2014), albeit they can have the same sequence (Tycko and
Wickner, 2013). Importantly, they can be self-propagating (Chien
et al., 2003, 2004; Colby and Prusiner, 2011; Collinge, 2010;
Collinge and Clarke, 2007; Cushman et al., 2010; Eisenberg and
Jucker, 2012; Gill, 2014; Greenwald and Riek, 2010; Le et al., 2015;
Makarava and Baskakov, 2008; Moda et al., 2015; Petkova et al.,
2005; Poggiolini et al., 2013; Sano et al., 2014; Toyama et al.,
2007; Toyama and Weissman, 2011; Tycko, 2015; Weissmann,
2005; Wickner et al., 2014; Wiltzius et al., 2009). Even amyloido-
genic proteins as small as Ab1-40 can adopt as many as ﬁve stable
conformations (F€andrich et al., 2009; Kodali et al., 2010; Meinhardt
et al., 2009; Reinke and Gestwicki, 2011), that can vary in terms of
protoﬁlament number, arrangement and structure (F€andrich et al.,
2009), as can a model 17mer (Kammerer et al., 2004; Kammerer
and Steinmetz, 2006; Verel et al., 2008). Clearly self-seeding can
propagate similar conformations (Maji et al., 2009).
Many proteins are potentially amyloidogenic (Tzotzos and Doig,
2010). Thus, an increasing number of human diseases is known to
be associated with misfolded or amyloid-type proteins (Chiti and
Dobson, 2006; Herczenik and Gebbink, 2008; Knowles et al.,
2014; Moreno-Gonzalez and Soto, 2011; Nienhuis et al., 2016;
Olanow and Brundin, 2013; Rambaran and Serpell, 2008; Tipping
et al., 2015). There are commonalities, in that amyloid proteins can
cross-seed each other's polymerisation (e.g. (Frost and Diamond,
2010; Hu et al., 2015; Liu et al., 2007; Lundmark et al., 2005;
Morales et al., 2013, 2015; Murakami et al., 2015; Murakami et al.,
2014; Ono et al., 2012a; Soto et al., 2006; Westermark et al.,
2009; Zhang et al., 2015a)). By contrast, “expression of two PrPC
moieties subtly different from each other antagonizes prion repli-
cation, and humans heterozygous for a common Prnp poly-
morphism at codon 129 are largely protected from CJD” (Aguzzi and
Haass, 2003). Commonalities between prion proteinmisfolding and
other protein misfolding diseases (AD, PD, ALS, etc (Prusiner et al.,
2015)) that lead to amyloids are widely recognised; however,
because the latter are not thought to be strictly infectious between
individuals or across species, they have sometimes been referred to
as prionoid diseases (Aguzzi and Lakkaraju, 2016; Ashe and Aguzzi,
2013). This said, their effects are clearly transmissible if injected
(Eisele et al., 2015; Murakami et al., 2014, 2015; Soto, 2012; Soto
et al., 2006; Sponarova et al., 2008; Westermark et al., 2009) (and
see above). For completeness, in biotechnology, one should add
that amyloid formation can interfere with the activity of protein
biologics (e.g. (Nielsen et al., 2001a, 2001b, 2001c; Wang, 2005)),
that bacterial inclusion bodies of recombinant proteins can also
contain b-amyloid structures (e.g. (de Groot et al., 2009; Morell
et al., 2008; Ventura and Villaverde, 2006; Wang, 2009; Wanget al., 2008)), and that at least some amyloid proteins are in fact
beneﬁcial to the host (Fowler et al., 2007).
b-structures are inherently stable (Tsemekhman et al., 2007). A
characteristic “cross-b” X-ray diffraction pattern is observed from
amyloid ﬁbres (Maji et al., 2009; Tycko and Wickner, 2013). A
diffuse reﬂection at 4.7e4.8 Å spacing comes from extended protein
chains running roughly perpendicular to the ﬁbril and spaced
4.7e4.8 Å apart. A more diffuse reﬂection at 10 Å illustrates that the
extended chains are organized into sheets spaced ~10 Å apart
(Eisenberg and Jucker, 2012; Langkilde et al., 2015; Morris and
Serpell, 2012; Serpell, 2000; Stromer and Serpell, 2005). Howev-
er, it is possible to form b-structures in multiple ways, that underlie
the different more-or-less stable conformations (Eisenberg and
Jucker, 2012).
The ﬁrst kind of conformational variation or polymorphism
(Eisenberg and Jucker, 2012) is packing polymorphism. Here, an
amyloid segment packs in two or more distinct ways, producing
ﬁbrils with different structures and distinctive properties, most
simply as a registration shift in which the two sheets forming the
steric zipper in the second polymorph shift their interdigitation
from that in the zipper of the ﬁrst polymorph, e.g. by a couple of
amino acids. The second structural model for strains is termed
segmental polymorphism; here, two or more different segments of
an amyloid protein are capable of forming spines, and do so, leading
to different ﬁbril structures. Finally, in a third type of amyloid
polymorphism, heterosteric zippers, the zipper is formed from the
interdigitation of nonidentical b-sheets.
As well as by quite subtle changes in sequence (Alexander et al.,
2009; Gill, 2014), the ﬁbril morphology is determined by environ-
mental factors, such as pH (Kammerer et al., 2004; Verel et al.,
2008), charge-neutralising polyanions (Groveman et al., 2015;
Silva et al., 2011), temperature (Kammerer et al., 2004; Verel
et al., 2008), agitation (Ladner-Keay et al., 2014), salts (Klement
et al., 2007), lipids (Gursky, 2015; Levine et al., 2015), other co-
solutes (Chiti et al., 1999), small molecule additives (Doig and
Derreumaux, 2015) or even quite large protein sequences (and
see below). To this end, a bacteriophage motif may be signiﬁcantly
anti-amyloidogenic and capable of remodelling formed amyloids
(Krishnan et al., 2014). At all events, the hallmark of these kinds of
amyloidogenic behaviour (Jucker and Walker, 2013) is the conver-
sion of a soluble protein, typically a monomer, into an insoluble
form that typically forms oligomers, protoﬁlaments and then
insoluble ﬁbrils.
In summary, it is increasingly recognised that proteins can self-
organise into ﬁbrils that require only a conformational change (no
sequence changes) and that these can vary as a function of both the
sequence and environmental conditions. However, many of these
processes occur on a rather sluggish timescale.
Another area in which a soluble precursor (ﬁbrinogen) is con-
verted into insoluble ﬁbres (ﬁbrin) occurs during the terminal
stages of blood clotting. Perhaps surprisingly, this has not really
been seen as a useful model for prion and amyloidogenic diseases,
and certainly ﬁbrin alone cannot ‘seed’ the growth of ﬁbrin mole-
cules, as each ﬁbrinogen molecule added to the growing ﬁbril re-
quires that thrombin ﬁrst releases two ﬁbrinopeptides (see below).
It is also a process that is necessarily and typically considerably
quicker than classical amyloidogenesis. However, the main pur-
poses of the present review are (i) to highlight the commonalities
that do exist, and (ii) to illustrate in particular the very substantial
changes in ﬁbre morphology, including the recently discovered
amyloid formation, that can be elicited by simple, and in many
cases highly substoichiometric additions of small molecules. We
believe that this will admit a substantial and useful cross-
fertilisation of these ﬁelds. We highlight in particular the facts
that (a) blood is much more easily available and amenable to study
Fig. 3. The coagulation cascade showing the ﬁnal conversion of ﬁbrinogen to ﬁbrin.
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bacterial lipopolysaccharide (LPS), may be involved in both blood
clotting and amyloidogenesis, and thus contribute to shared aeti-
ologies. A preprint has been lodged in bioRxiv (Kell & Pretorius
2016).2. The terminal stages of normal blood clotting: ﬁbrinogen,
ﬁbrin and thrombin
The terminal stage of the coagulation cascade involves the
conversion of ﬁbrinogen to ﬁbrin strands, and this involves a
number of regulated steps (see Fig 3). Both the expansion and
strength of the ﬁnal clot is ﬁnely regulated and depends mostly on
the conversion of ﬁbrinogen to ﬁbrin under the enzymatic action of
thrombin, which (apart from a subsequent crosslinking induced by
the transglutaminase factor XIII) is the ﬁnal step in the cascade.
Fibrinogen circulates at high concentrations 2e4 mg.L1
(Walton et al., 2015) or at about 9 mM in the plasma (Ferri et al.,
2002; Neeves et al., 2010), with a molecular mass of around
340 kDa. It has a centrosymmetric, trinodular, S-shaped structure
that is 46 nm in length and 4.5 nm in diameter (Guthold et al.,
2007). During coagulation, thrombin cleaves two N-terminal pep-
tides from the Aa- and Bb-chains, promoting the formation of
protoﬁbrils and subsequently ﬁbrin ﬁbres (Litvinov et al., 2007;
Undas and Ari€ens, 2011).
The ﬁbrinogen protein consists of two sets each of three poly-
peptide chains (Aa, Bb, g)2 (Walton et al., 2015), linked by 29 S-S
bonds (Litvinov et al., 2012) that has the basic structure shown in
Fig 4.
The main features are:
 A single central E-region, containing 6 N-termini and ﬁbrino-
peptides A and B Two D-regions ﬂanking the E-region; each D-region contains a
globular b C-terminal domain (b197e461; called bC) and the
globular g C-terminal domain (g143e411; called gC), both of
which consist of a b-sheet core ﬂanked by a few small a-helices
(Guthold et al., 2007).
 Two coiled coils consisting each of three a-helices; these coils
connect the E and D-regions.
 There are also 29 disulphide bonds that acts as stabilizers; and 5
of these disulphide bonds are within the central E-nodule that
forms a link between the two halves of the molecule.
 There are also 4 disulphide rings, consisting of 3 disulphide
bonds that link the a-to the b-chain, the a-to the g-chain, and
the b-to the g-chain. This forms a supporting unit that keeps the
three a-helices in the coiled coils together in each ﬁbrinogen
molecule; 1 ring at each end of the two coiled coils.
 Twelve intra-chain disulphide bonds, 3 in each of the 2 globular
bC domains of the D-regions, 2 in each of the two globular gC
domain of the D-regions, and one in each of the two aC domains.
Thrombin cleaves the ﬁbrinogen, resulting in the ﬁbrin mono-
mers containing Aa, Bb and g polypeptides, which are then curved
into the central E-region containing the 2 distal D-regions (Yang
et al., 2001; Yeromonahos et al., 2010). Fibrin monomers are
formed on the removal of 2 pairs of ﬁbrinopeptides (ﬁbrinopeptide
A and B from the N-termini of the Aa and Bb chains), converting it
into a ﬁbrin monomer that immediately polymerizes by self-
assembly, to form a complex or a meshwork of ﬁbrin ﬁbres.
Importantly, however, the ﬁbrin monomer maintains major struc-
tural features of ﬁbrinogen, including the coiled-coils (Litvinov
et al., 2012). When the 2 ﬁbrinopeptides are removed from the
N-terminal region of the Aa- and Bb-chains, knoblike binding sites
A and B, are exposed (Guthold et al., 2007). Finally, an insoluble
ﬁbrin gel complex is formed when the ﬁbrin strands aggregate and
Fig. 4. Diagrammatic representation of ﬁbrinogen packaging into the ﬁnal product, the cross-linked ﬁbrin mesh.
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XIIIa (Dickneite et al., 2015; Ferry and Morrison, 1947; Fowler et al.,
1981; Neeves et al., 2010; Phillips et al., 2003; Weisel, 1986).
Plasma FXIII (ﬁbrin stabilizing factor) is a plasma trans-
glutaminase (Dickneite et al., 2015) and consists of two catalytic
subunits (FXIII-A) and two non-catalytic subunits (FXIII-B) that are
tightly connected in a non-covalent, heterotetramer (FXIII-A2B2).
All FXIII-A2B2 in the circulation are bound to ﬁbrinogen (Walton
et al., 2015). FXIII-A2B2 is activated by thrombin-catalyzed release
of N-terminal peptides from the FXIII-A subunits and calcium-
mediated dissociation of the FXIII-B subunits, yielding activated
FXIII-A2 (or FXIIIa) (Walton et al., 2015).
Both plasma- and platelet-derived FXIIIa catalyse the formation
of ε-N-(g-glutamyl)-lysyl crosslinks within ﬁbrin (Walton et al.,
2015) and this crosslinking stabilizes ﬁbrin ﬁbres and therefore
clots (Walton et al., 2015). XIIIa has profound effects on ﬁbrin
integrity and it seems that g- and a-chain crosslinking make
distinct contributions to clot function and structure (Richardson
et al., 2013; Standeven et al., 2007). FXIIIa therefore plays in
important role in the regulation of thrombus stability, regulation
and cell-matrix interactions, including wound healing (Richardson
et al., 2013).
Recently, it was found that unperturbed (human) ﬁbrin contains
30± 3% a-helices, 37± 4% b-sheets, and 32± 3% turns, loops, and
random coils (Litvinov et al., 2012). As discussed in detail later,
under certain physiological (and also pathological) conditions,
ﬁbrin clots may undergo deformation, where molecular unfolding
may occur (Litvinov et al., 2012; Zhmurov et al., 2011, 2012). Sec-
ondary structural alterations including the a-helices to b-sheets
transition, is a common mechanism of protein structural rear-
rangement. Increased force can result in the uncoiling of the a-
helices (or coiled coils) resulting in an increase of b-sheets. How-
ever, the simple binding of the ﬁbrinopeptides to their corre-
sponding holes on the D-regions does not result in any signiﬁcant
increase in b-sheets (See Fig 5 for a visual representation of whenthe formation of increased b-sheets and the uncoiling of the a-
helices does occur, e.g. under mechanical loading.)
These deformations affect the viscoelasticity at both the ﬁbre
and molecular levels and will translate into functional changes at
the whole clot level. They also have implications for systemic
changes of coagulation. Therefore, during the molecular extension
of ﬁbrin, a-helix to b-strand conversion occurs in coiled-coils and
during both mechanical elongation and compression of ﬁbrin clots,
a rearrangement of the secondary clot structure occurs, comprising
mainly the a-helix-to-b-sheet transition (Litvinov et al., 2012). The
authors suggested that the a-b transition followed by formation of
an intermolecular b-sheet structure and protein aggregation could
be a common mechanism underlying the different types of ﬁbrin
deformation (Litvinov et al., 2012). Here, we suggest that this may
be the fundamental underlying reason for different ﬁbrin ﬁbre ul-
trastructures that we have previously reported on, where we found
a changed macroscopically observable ﬁbrin ﬁbre structure during
various systemic inﬂammatory conditions.
Many excellent reviews exist on the mechanisms of clot for-
mation and basic structure (e.g. (Cilia La Corte et al., 2011; Undas,
2014; Undas and Ari€ens, 2011; Undas et al., 2011; Weisel, 2005,
2007; Wolberg, 2007; Wolberg, 2012)), ﬁbrinolysis (Chapin et al.,
1989; Longstaff and Kolev, 2015; Undas et al., 2008), and the
importance of clotting in vascular diseases (Ari€ens, 2011, 2013;
Bridge et al., 2014). Because of this, we can be relatively brief, and
focus on the nub of our review, which is the argument that, like
prions, ﬁbrinogen can, under certain circumstances, form beta-
sheet-rich amyloid ﬁbrils.
3. Methods for determining the clotting process
Studying clot formation and degradation, using either plasma or
whole blood, is important in the treatment of hyper-as well as
hypocoagulability, and both optical and rheological/viscoelasto-
metric methods have been developed (e.g. (Bates and Weitz, 2005;
Fig. 5. The a-helices to b-sheets phase transition in ﬁbrin formation under deformation of e.g. low (healthy coagulation) and high force (pathological coagulation) (adapted from
(Zhmurov et al., 2012)).
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2008; McMichael and Smith, 2011)); for a recent review, see (Kell
and Pretorius, 2015b). Currently, visco-elastic technologies are
mainly used as point-of-care tests with immediately-available re-
sults; these include prothrombin time (PT), activated partial
thromboplastin time (APTT), thromboelastography (TEG) and
thromoboelastometry (ROTEM). Analyses that use plasma obtain
results based on PT and APTT (Johansson et al., 2009); however, PT
and APTT only test the coagulation protein component of the sys-
tem, and results have to be interpreted carefully in the context of
the clinical presentation and assay limitations (Chee, 2014).
Consequently, we rather favour the use of viscoelastic haemostatic
methods such as TEG (Afshari et al., 2011; Bolliger et al., 2012;
Johansson et al., 2009; Reikvam et al., 2009; Sankarankutty et al.,
2012), ROTEM (Afshari et al., 2011; Sankarankutty et al., 2012;
Sørensen and Ingerslev, 2005; van Veen et al., 2009) and the
Sonoclot (Hett et al., 1995; Kjellberg and Hellgren, 2000; Sharma
et al., 2013).
In the past, EP's laboratory has focussed speciﬁcally on using the
TEG (Bester et al., 2015; de Villiers et al., 2016; Nielsen andTable 1
TEG parameters typically generated for whole blood and platelet poor plasma (Bester et
Thromboelastic parameters
R value: reaction time Minutes Time of latency fro
K: kinetics Minutes Time taken to achi
А (Alpha): Angle (slope between
thetraces represented by R and K) (
Angle in degrees The angle measure
hence assesses the
MA: Maximal Amplitude mm Maximum strength
i.e. overall stability
Maximum rate of thrombus generation
(MRTG)
Dyn.cm2.s1 The maximum vel
using G, where G i
Time to maximum rate of thrombus
generation (TMRTG)
Minutes The time interval o
Total thrombus generation (TTG) Dyn.cm2 The clot strength:
generated during c
growth, representi
Lysis 30 (LY30) % Percentage lysis obPretorius, 2014a, 2014b; Nielsen et al., 2015; Swanepoel et al.,
2015). See Table 1 for a comprehensive list of measurements that
can be done using thromboelastography.
Another important technique that we have combined with the
TEG results, with great success, is scanning electron microscopy of
ﬁbrin ﬁbre structure (Bester et al., 2015; de Villiers et al., 2016;
Kell and Pretorius, 2015a, 2015b; Nielsen and Pretorius, 2014a;
Nielsen and Pretorius, 2014b; Nielsen et al., 2015; Potgieter
et al., 2015; Pretorius et al., 2014a, 2016b, 2016c; Pretorius et al.,
2013; Swanepoel et al., 2015). These methods give a visual rep-
resentation of clot structure, where the ﬁbrin packaging can be
studied at high resolution and magniﬁcation, and have illustrated
the very great differences that can be observed in plasma
from diseased vs healthy controls. As mentioned in the previous
paragraphs, PT, PTT, TEG, as well as ROTEM have been used suc-
cessfully as point-of-care methods, while electron microscopy has
been used mostly in the laboratory. However, the usefulness
of combining the technologies in an integrated approach is clear
(de Villiers et al., 2016; Pretorius et al., 2016d; Swanepoel et al.,
2015).al., 2015; de Villiers et al., 2016).
m start of test to initial ﬁbrin formation (amplitude of 2 mm); i.e. initiation time
eve a certain level of clot strength (amplitude of 20 mm); i.e. ampliﬁcation
s the speed at which ﬁbrin build up and cross linking takes place,
rate of clot formation; i.e. thrombin burst
/stiffness of clot. Reﬂects the ultimate strength of the ﬁbrin clot,
of the clot
ocity of clot growth observed or maximum rate of thrombus generation
s the elastic modulus strength of the thrombus in dynes per cm2
bserved before the maximum speed of the clot growth
the amount of total resistance (to movement of the cup and pin)
lot formation. This is the total area under the velocity curve during clot
ng the amount of clot strength generated during clot growth
tained 30 min after MA
Fig. 6. Examples of amyloid staining reagents.
Table 2
Wavelengths that have commonly been used for excitation and emission when
assessing Thioﬂavin T interaction with b-amyloids.
Excitation (nm) Emission (nm) References
455 485 (Ban et al., 2003)
440 490 (Berthoumieu et al., 2015)
440 485 (Biancalana et al., 2009)
435 480 (Di Carlo et al., 2015)
450 460e600 (Groenning et al., 2007)
440 460e570 (Jha et al., 2011)
440 490 (Jha et al., 2014)
450 482 (LeVine, 1993)
440/20 485/20 (LeVine, 1997)
440e450 480e490 (Lindberg et al., 2015)
450 482 (Naiki et al., 1989)
445 485 (Ozawa et al., 2011)
440 485 (Palhano et al., 2013)
450 480 (Sabate and Ventura, 2013)
449 480 (Sulatskaya et al., 2011)
440 <600 (Younan and Viles, 2015)
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As with ﬂuorescent proteins such as GFP, the ability to detect
amyloid (and cross-b motifs more generally) by optical means
would improve their ease of study enormously (Hammarstr€om
et al., 2013). Fortunately, a number of appropriate dyes are
known (Fig 6).
Congo Red (Bely and Makovitzky, 2006; Frid et al., 2007; Howie
and Brewer, 2009; Howie et al., 2008; Howie and Owen-Casey,
2010; Inouye and Kirschner, 2005; Kelenyi, 1967; Maezawa et al.,
2008; Nilsson, 2004;Wu et al., 2012a) (CR) was one of the ﬁrst dyes
known to bind to amyloid (Puchtler and Sweat, 1966). Its name
derives (Steensma, 2001) from the marketing activities of the
Berlin-based AGFA textile dyestuff company in 1885, following
various geopolitical events of that time, but otherwise has no
connection with central Africa. Bennhold (Bennhold, 1922) was the
ﬁrst to describe its binding to amyloid. This induces a characteristic
shift in CR's maximal optical absorbance from 490 nm to 540 nm,
and rather variable (Howie, 2015; Howie and Brewer, 2009; Howie
et al., 2008; Howie and Owen-Casey, 2010) birefringence and di-
chroism. As Howie and Brewer rather nicely put it (Howie and
Brewer, 2009), “Amyloid stained by Congo red has striking optical
properties that have mostly been badly described and inadequately
explained”, although in general terms the birefringence clearly
reﬂects the binding to the oriented b-sheets, with the orientation
being increased by the practice of making smears. There is evidence
for the particular involvement of histidine residues (Inouye and
Kirschner, 2005; Inouye et al., 2000). Because the colours seen
vary rather markedly with the relative orientations of polariser and
analyser in the birefringence measurements (Howie, 2015; Howie
and Brewer, 2009; Howie et al., 2008; Howie and Owen-Casey,
2010), and although apparently preferred as a ‘gold standard’ by
histologists, CR is seen as a stain that is less than perfectly repro-
ducible, and at least for research it has largely been overtaken by
ﬂuorescent stains. This said, we note with interest a recent
‘smartphone’ assay application (Acestor et al., 2016; Jonas et al.,
2016; Rood et al., 2015).
3.2. Thioﬂavin S, thioﬂavin T and derivatives
The thioﬂavin stains (based on a thiazole nucleus) probablycount most nearly as “God's gift to students of amyloid and amy-
loidogenesis”. Free thioﬂavin T (ThT) ﬂuoresces faintly with exci-
tation and emission maxima of 350 and 440 nm, respectively,
whereas upon interaction with amyloid ﬁbrils a substantially
enhanced ThT ﬂuorescence is observed, with excitation and emis-
sion maxima at about 440/450 and 480/490 nm, respectively
(Groenning, 2010; Khurana et al., 2005; Kuznetsova et al., 2016,
2012a, 2012b; LeVine, 1997; LeVine, 1999; Lindberg et al., 2015;
Naiki et al., 1989; Palhano et al., 2013; Picken and Herrera, 2012;
Robbins et al., 2012; Sulatskaya et al., 2011, 2012; Wolfe et al.,
2010; Younan and Viles, 2015; Zhang and Ran, 2013). Table 2
summarises the wavelengths used in a number of studies.
As with CR, the ﬂuorescence enhancement is caused by binding
to oriented b-rich ﬁbrils. Fig 7 shows the conversion of typical
amyloid-free ﬁbrin ﬁbres to highly-amyloid-rich ones as judged by
their staining with ThT, added to plasma from a patient with
thromboembolic stroke (Fig 7B) and compared with the same
treatment of plasma from a matched, healthy control. The differ-
ence is rather striking.
As a dibenzothiazole dye (Wu et al., 2007), Thioﬂavin S (ThS) is a
somewhat extended version of ThT (Fig 6). We are not aware of any
Fig. 7. Fibrin ﬁbres from a healthy individual (A) and an individual who had suffered a thromboembolic stroke (B), stained with ThT (5 mM exposure concentration) and viewed
using a confocal microscope. Scale bar: 10 mm.
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for tissue staining (Sun et al., 2002). Consequently, it may seem
sensible to use the smaller dye. Protein transporters are required to
get xenobiotics into cells (Dobson and Kell, 2008; Kell et al., 2011,
2013; Kell and Oliver, 2014). For tissue staining, even ThT does
not penetrate the blood-brain barrier, and a neutral version known
as Pittsburgh compound B (PIB) (Fig 6) has been developed that can
(Mathis et al., 2003; Murray et al., 2015; Wu et al., 2011). (Based on
its structure and the analyses presented elsewhere (O'Hagan and
Kell, 2015; O'Hagan and Kell, 2016; O'Hagan et al., 2015), the
three Recon 2(.2) metabolites (Swainston et al., 2013, 2016; Thiele
et al., 2013) and marketed drugs to which it is most similar are
given in Fig 8.) However, while its 11C-derivative has been widely
used in PET imaging of ﬁbrils (e.g. (Driscoll et al., 2012; Grimmer
et al., 2009; Mathis et al., 2007; Murray et al., 2015; Resnick et al.,
2010; Wu et al., 2011)), PIB lacks the large optical absorbanceFig. 8. The three endogenous metabolites and marketed drugs most closely related to PIB, ashift and ﬂuorescence enhancement characteristic of ThS and ThT
(Wu et al., 2011).
Other amyloid-selective dyes that have been used include X-34
(Excitation 400nm/Emission 455 nm), which is in fact a ﬂuorescent
derivative of CR (Ikonomovic et al., 2006; Link et al., 2001; Styren
et al., 2000), chrysamine G (Kang and Han, 2001; Klunk et al.,
1994) (Fig 6) (which is excited at 386 nm) and ANCA (excitation
380e430, emission 525e550). Since most of these latter are not
commercially available, it is not obvious that these dyes bring great
beneﬁts over ThT. This said, it is normally desirable to be able to
excite nearer the red (Kovalska et al., 2012; Ono et al., 2012b;
Rajasekhar et al., 2016) or beyond (Guo et al., 2014; Staderini
et al., 2015; Watanabe et al., 2013; Yuan et al., 2013b; Zhang
et al., 2015b) to decrease autoﬂuorescence, and such dyes are
likely to be very useful as they become more widely available.
In an interesting development, Stefansson and colleaguess assessed using the MACCS encoding (Durant et al., 2002) and the Tanimoto distance.
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to binding (Wolfe et al., 2010), and (ii) that a number of modern,
sensitive DNA-intercalating dyes also contain the thiazole nucleus.
They showed (Stefansson et al., 2012) that these dyes too would
bind to b-amyloid ﬁbrils, albeit not normally (but cf (Lindberg and
Esbjorner, 2016)) with quite with the same ﬂuorescence enhance-
ment as shown by ThT. However, they could be used in combination
with ThT to increase the Stokes shift (via ﬂuorescence resonance
energy transfer) quite hugely into the red. Note though that the
binding of these (Reuter and Dryden, 2010) and related dyes (Twist
et al., 2004) to double-stranded DNA can be detected at the level of
the single molecule, so such DNAmust be absent. There is no doubt
that continuing improvements in dye development will be of
considerable value to the ﬁeld.
3.3. Luminescent conjugated thiophenes
In an interesting and important development, Nilsson and col-
leagues (e.g. (Berg et al., 2010; Klingstedt et al., 2011, 2013a;
Klingstedt and Nilsson, 2012; Nilsson et al., 2005, 2006, 2007,
2009, 2010, 2012; Shirani et al., 2015; Simon et al., 2014;
Sj€olander et al., 2015, 2016)) have introduced a series of lumines-
cent oligothiophenes and polythiophenes. As well as possessing
excellent optical properties, they seem preferentially to stain the
smaller oligomers (Klingstedt and Nilsson, 2012) that may be more
cytotoxic (see below). They can also be used to discriminate
different ﬁbres and conformational states optically (e.g. (Åslund
et al., 2007, 2009; Klingstedt et al., 2013a, 2013b, 2015; 2012;
Magnusson et al., 2014)). Consequently, these and related mole-
cules seem to bewell worth exploring as part of the next generation
of amyloid-selective dyes, not least in the context of super-
resolution (Ries et al., 2013).
4. The conversion of ﬁbrinogen to ﬁbrin is normally not a
transition from a-helices to b-sheets except in special
circumstances that include mutants
A clear characteristic of the conversion of amyloidogenic pro-
teins to genuine insoluble amyloids is the conversion of structures
with (typically) predominantly a-helices to structures with a
(much) greater b-sheet content. The obvious question is to what
extent is this similarly true in normal and abnormal clotting
processes?
As seen in the section on normal blood clotting, the chief
mechanism involves a ‘knobs and stalks’ interaction (that includes
the ability to repair ﬁbrils isoenergetically (Chernysh et al., 2012)),
and that does not of itself require, nor does it seemingly provide,
anymajor conformational changes in the secondary structure of the
ﬁbrinogen monomers (Averett et al., 2008, 2009; Protopopova
et al., 2015; Weisel, 2005; Yermolenko et al., 2011). In a similar
vein, normal blood clotting is not considered to be an amyloido-
genic process, except in very rare cases of particular mutants of the
ﬁbrinogen a chain (Benson et al., 1993; Gillmore et al., 2009;
Haidinger et al., 2013; Hamidi Asl et al., 1997; Picken, 2010;
Serpell et al., 2007; Stangou et al., 2010).
5. Mechanical stretching can induce an a-to-b transition in a
large variety of biopolymers
As judged by infrared spectroscopy of the various amide bands,
standard human ﬁbrin is about 30% a-helix, 40% b-sheet and 30%
turns (Bramanti et al., 1997), similar to the numbers given (above)
by Litvinov et al. (Litvinov et al., 2012). This percentage changes
with pressure and mechanical unfolding (Litvinov et al., 2012;
Zhmurov et al., 2011, 2012), but only at extremes of stretching(that apparently do not happen in normal clot formation) are the
mechanical properties of ﬁbrin considered to reﬂect an a-to-b
transition (Guthold et al., 2007; Kreplak et al., 2004; Liu et al., 2010;
Miserez and Guerette, 2013). Speciﬁcally, at a certain extension
there is what amounts to a phase transition. To this end, there were
also some striking nonlinearities noted in the detailed studies of
Münster and colleagues (Münster et al., 2013) and of Kim and
colleagues (Kim et al., 2014).
It is of some interest that mechanical forces can also be used to
effect an a-to-b transition in prions (Tao et al., 2015) and a variety of
other elastomeric biopolymers (Feughelman, 2002; Hearle, 2000;
Miserez and Guerette, 2013; Qin and Buehler, 2010), not least ker-
atin (Bendit, 1957, 1960; Kreplak et al., 2004; Paquin and Colomban,
2007). It is particularly noteworthy that after two- and three-fold
longitudinal stretching the median ﬁbre diameter and pore area
in SEM images of ﬁbrin decreased two-to three-fold (Varjú et al.,
2011), just as in a number of the disease states mentioned above,
and that this conferred proteolytic resistance to the ﬁbrin,What the
above examples tell us is that under normal circumstances human
ﬁbrin does not adopt a form that has a b-sheet content greater than
~40%, but that it can indeed do so under the appropriate circum-
stances. What we shall see below, is that these are considerably
more common than had previously been surmised.
5.1. Effects of ﬂow on ﬁbrin properties
The above studies involved mechanical stretching, but (given
that blood does ﬂow in the circulation) there has been some in-
terest in the effects of ﬂow (velocity) on ﬁbrin structure. Increases
in ﬁbre thickness. Hints of b-sheet formation induced by ﬂow can
be seen in (Badiei et al., 2015), while in a very striking study,
Campbell et al. (Campbell et al., 2010). saw a huge increase in the
ﬂow-induced diameter of ﬁbrin ﬁbres, from a mean of 79e226 nm.
6. When clotting goes wrong: hypercoagulability and
hypoﬁbrinolysis in chronic, inﬂammatory diseases
In inﬂammatory conditions, hypercoagulability, as well as
hypoﬁbrinolysis is a common phenomenon and both are seen as
coagulopathies; see (Kell and Pretorius, 2015b) for a table with a
comprehensive list of inﬂammatory diseases with both known
hypercoagulable and hypoﬁbrinolytic characteristics. Our partic-
ular interest has been the study of clot structure using scanning
electron microscopy, and we have noted that this method shows us
precisely the diameter of individual ﬁbrin ﬁbres, as well as the
general clot architecture (e.g. (Lipinski and Pretorius, 2013a, 2013b;
Lipinski et al., 2012b; Pretorius, 2011; Pretorius et al., 2014a;
Pretorius and Lipinski, 2013a; Pretorius and Oberholzer, 2009;
Pretorius et al., 2010a, 2010b, 2011a, 2011b)). We and others have
shown that the diameter of ‘typical’ healthy ﬁbrin ﬁbres is
80e110 nm (Bester et al., 2015; Kell and Pretorius, 2015b; Pretorius
et al., 2011c; Weigandt et al., 2012) (those of most amyloidogenic
proteins are more like 10e20 nm or less, e.g. (Engel et al., 2008;
Foguel et al., 2003; Ivanova et al., 2004; Klement et al., 2007;
Kollmer et al., 2016; Uversky et al., 2001)), while during inﬂam-
mation, clot diameter changes. It may be increased, as seen in
Alzheimer's type dementia (Bester et al., 2015), or decreased as
seen in stroke (Pretorius et al., 2011c). Up to now we have had no
knowledge of the exact molecular conformational changes (e.g. the
a-helices and b-sheets) that happen during inﬂammation; we have
just reported on the more macroscopically observable structural
changes that are visible in the different conditions (See Fig 9). Now
it has become clear that the exact changes that happen during
inﬂammation in the a-helix and b-sheet interaction involve major
changes in secondary structure, and might be of great importance
Fig. 9. Representative micrographs of different inﬂammatory conditions. A) Healthy ﬁbrin ﬁbre structure; B) thromboembolic stroke; C) Alzheimer's type dementia; D) Type II
diabetes. White arrows: ﬁne netted areas; Red arrow: areas where ﬁbrin ﬁbres are thicker. Scale bar: 1 mm.
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In vivo, as part of normal wound healing, the clot is removed via
the ﬁbrinolytic system and this process is mediated by the serine
protease plasmin, which cleaves the ﬁbrin molecule at speciﬁc sites
(Bucay et al., 2015; Draxler and Medcalf, 2015) to form a variety of
degradation products collectively referred to as D-dimer (Adam
et al., 2009; Walker and Nesheim, 1999). (Whether D-dimer can
adopt a b-sheet of amyloid form is apparently unknown, and its
concentration varies but little during amyloidosis (Suga et al.,
2012)). During ﬁbrin polymerisation, normally cryptic plasmin-
ogen and plasmin binding sites are exposed. These binding sites are
situated on the aC regions that contain lysine-dependent tPA- and
plasminogen-binding sites (Bucay et al., 2015; Medved and
Nieuwenhuizen, 2003). During ﬁbrinolysis, plasmin initially
cleaves the aC regions, and then cleaves the three polypeptide
chains connecting the E-domains and the D-domains (Bucay et al.,
2015; Nieuwenhuizen, 2001). The exact process of ﬁbrinolysis is
controlled by various structural arrangements and physical prop-
erties of the clot itself. These properties include clot density, stiff-
ness and ﬁbrin ﬁbre diameter (Collet et al., 2003; Veklich et al.,
1998; Weisel, 2007). Bucay and co-workers in 2015 found that if
ﬁbres are exposed to plasmin, thin ﬁbres are easily cleaved, and that
thicker ﬁbres grew in length during ﬁbrinolysis. Therefore the lytic
susceptibility of a ﬁbre is directly related to the intrinsic strain on
the ﬁbre resulting from the polymerisation process (Bucay et al.,
2015). Here we also suggest that the lysine-dependent tPA- and
plasminogen-binding site accessibility on the ﬁbrin ﬁbres will be
crucial for successful ﬁbrinolysis and therefore the arrangement of
the a-helix and b-sheets will be of fundamental importance in this
process. The difﬁculty or resistance of hydrolysis of abnormal ﬁbrin
clots can be directly compared to this ‘hypohydrolysis” (proteinase
K resistance) characteristic of PrPSc, discussed in detail above.
As summarised by Campbell and colleagues (Campbell et al.,
2010), diameter per se can affect ﬁbrinolysis rates: “Fibre diam-
eter and network density play signiﬁcant roles in clot dissolution
(Weisel and Litvinov, 2008). Compared to thin ﬁbres, thick ﬁbressupport faster plasmin generation rates. Plasmin lyses ﬁbrin via
laterally transecting individual ﬁbres. Thin ﬁbres lyse faster than
thick ﬁbres; however, coarse networks of thick ﬁbres lyse faster
than tight networks of thin ﬁbres (Collet et al., 2000).”However, we
suggest here that it may also be secondary structure that plays the
major role.
One of the most damaging forms of hypercoagulation is known
as disseminated intravascular coagulation (Asakura, 2014; Bick,
2002; Kaneko and Wada, 2011; Levi and van der Poll, 2013a;
Wada et al., 2014). It is essentially a runaway form of hyper-
coagulation, and it too may be induced by LPS (endotoxin)
(Asakura, 2014; Duburcq et al., 2015; Wu et al., 2012b, 2014; Yu
et al., 2013). There is signiﬁcant evidence that it can itself lead to
multiple organ failure and death (Gando, 2010). It does not yet
seem to be known, but seems probable, that the form of ﬁbrin in
DIC is indeed a b-amyloid.
Clot retraction. Clot retraction (contraction) is a physiological
process initiated by platelets that results in compaction of the ﬁbrin
network and expulsion of the majority of serum from the clot -
together with the majority of unbound plasminogen, typically over
a 24 h period in vivo (Cines et al., 2014). It reﬂects in part the
crosslinking of ﬁbrin effected by Factor XIII (Hethershaw et al.,
2014; Kasahara et al., 2010, 2013). According to Weisel (Weisel,
2011), commenting on the important Varjú paper (Varjú et al.,
2011), so-called retracted clots are much more resistant to lysis
(Kunitada et al., 1992; Sabovic and Blinc, 2000; Sabovic et al., 1989),
and retracted clots probably provide a useful model for events such
as stroke. Clots are much stiffer in diseases such as multiple
myeloma (Carr and Zekert, 1994; Lackner et al., 1970). It is not yet
apparently known whether clot retraction is accompanied by b-
sheet formation.
7. Mutual effects of ﬁbrin(ogen) on b-amyloid in Alzheimer's
disease
We rehearsed above how there was a limited (non-zero) cross-
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example of particular interest is given by the interaction between
ﬁbrin(ogen) and b-amyloid, as developed by Strickland and col-
leagues (Ahn et al., 2010, 2014; Cortes-Canteli et al., 2015; Cortes-
Canteli et al., 2010; Cortes-Canteli and Strickland, 2009; Cortes-
Canteli et al., 2012; Paul et al., 2007; Zamolodchikov and Strick-
land, 2012). We rehearse their highly important arguments and
ﬁndings in some detail.
As pointed out by Paul and colleagues (Paul et al., 2007),
ﬁbrinogen is present in the brains of AD patients (Fiala et al., 2002),
but the pathologic signiﬁcance is or was not known. Using mutant
mice, they showed the deﬁnite contribution of ﬁbrin to the aberrant
pathology (Paul et al., 2007). As is well known, the extracellular
plaques in the AD brain are composed mainly of a 40e42 amino
acid peptide, the b-amyloid or amyloid-b (Ab) peptide that is
derived proteolytically from the N-terminus of the so-called amy-
loid-b precursor protein (APP). There is little doubt (the ‘amyloid
hypothesis’ (Eisele et al., 2015; Hardy and Selkoe, 2002; Hardy and
Higgins, 1992; Jonsson et al., 2012; Minter et al., 2016; Selkoe and
Hardy, 2016)) that Ab plays some kind of signiﬁcant role in AD,
albeit that measures designed to remove it have not led to useful
therapeutics (Hardy, 2009; Herrup, 2015; Itzhaki et al., 2016;
Karran and Hardy, 2014; Karran et al., 2011). The probable reason
for this is simply that it is not the sole actor (though see Note Added
in Proof) (Nussbaum et al., 2013), and certainly its interactions with
iron salts are central to disease development and loss of cognition
(e.g. (Bush, 2003; Bush and Tanzi, 2008; Crapper McLachlan et al.,
1991; Fine et al., 2012; Guo et al., 2013; Jomova and Valko, 2011;
Kell, 2009, 2010; Kell and Pretorius, 2015b; Malecki and Connor,
2002; Pretorius et al., 2016a; Smith et al., 1997; Smith et al., 2010;
Valko et al., 2016)). ‘Iron’ interacts with ﬁbrinogen too (Nielsen
and Jacobsen, 2016; Pretorius et al., 2013, 2014a; Pretorius and
Kell, 2014), as does ferritin (Okada et al., 2015). Here we rehearse
and develop the additional idea that it is the interactions of Abwith
ﬁbrin(ogen), leading to amyloid ﬁbril formation, that may provide a
signiﬁcant contribution to the neurodegeneration.
An important starting recognition (Cortes-Canteli and
Strickland, 2009) is that plasma ﬁbrinogen levels are raised in AD
(Davalos and Akassoglou, 2012; Lee et al., 2007; Marioni et al.,
2009; Noguchi et al., 2014; van Oijen et al., 2005; Xu et al., 2008),
as is coagulability (Gupta et al., 2005; Kell and Pretorius, 2015b).
The extent of ﬁbrin deposition reﬂects the plasma ﬁbrinogen level
as it is modiﬁed by genetic or pharmacological means (Cortes-
Canteli and Strickland, 2009). Fibrinogen is also accumulated in
AD plaques (Paul et al., 2007; Ryu and McLarnon, 2009), and this
can promote neurodegeneration (Cortes-Canteli et al., 2015).
As well as its general intra- and extra-cellular deposition, a
common pathology in AD patients is the deposition of Ab in the
walls of capillaries, arteries, and arterioles. This is known as cere-
bral amyloid angiopathy (CAA) (Vinters, 1987). Strickland and col-
leagues next showed (Cortes-Canteli et al., 2010), both in vitro and
in vivo, that ﬁbrin clots formed in the presence of Ab were struc-
turally abnormal and resistant to degradation, and that lowering
ﬁbrinogen improved cognitive function (in mice). (It is also of in-
terest that Ab promotes the binding of tissue plasminogen activator,
which recognises cross-beta sheets (Kranenburg et al., 2002;
Longstaff and Kolev, 2015)). Thioﬂavin S (like thioﬂavin T, below)
is a stain for amyloid ﬁbrils based on their high b-sheet content
(Bussiere et al., 2004; Ly et al., 2011; Sun et al., 2002). Immuno-
logical staining of ﬁbrinogen and thioﬂavin S staining of (pre-
sumed) Ab showed colocalisation (Cortes-Canteli et al., 2010, 2012),
though of course this would not have distinguished whether the
ﬁbrin too had adopted a b-sheet form.
Strickland and colleagues next showed (Ahn et al., 2010) that Ab
speciﬁcally interacts with ﬁbrinogen (Kd ~ 26 nM), that the bindingsite is located near the C terminus of the ﬁbrinogen b-chain, and
that the binding causes ﬁbrinogen to oligomerise (albeit not to
standard ﬁbrin ﬁbres) and to deposit. Although the Ab will bind to
preformed clots, only when it is added before clotting does it
produce thinner ﬁbres in tighter networks (Zamolodchikov and
Strickland, 2012); it also attenuates plasminogen binding (again
consistent with the idea that it induces a structural change in the
ﬁbrinogen).
As is well known, the apoE4 allele is associated with a greater
risk of AD; brains from AD cases homozygous for the APOE ε4 allele
showed increased deposition of ﬁbrin(ogen), especially in CAA- and
Ab-positive blood vessels (Hultman et al., 2013), fully consistent
with the role of this process in cognitive decline. Similarly, phar-
macological inhibition with a small molecule called Ru-505 of the
ﬁbrinogen-Ab interaction both altered the clot morphology and
arrested cognitive decline (Ahn et al., 2014), implying the potential
value of this target (which is also susceptible to enzymatic degra-
dation (Bhattacharjee and Bhattacharyya, 2015)). Overall, the case
for an important role of ﬁbrin(ogen)'s interactionwith Ab as part of
the aetiology of AD seems very well made. For our purposes, there
are two chief questions: (i) what is the extent to which the ﬁbrin
adopts an amyloid form when in complex with Ab?, and (ii) is it
more the ﬁbrinogen that precipitates the Ab or the Ab that pre-
cipitates the ﬁbrinogen?
8. Small molecules that affect the nature of blood clotting
and ﬁbrin ﬁbres in vitro
The effects of small molecules (both those produced endoge-
nously and introduced drugs) on the coagulation system represent
a vast ﬁeld, and arguably warrant a review of their own, since
molecules binding to the normal forms may be expected to inhibit
toxic amyloidogenesis (Alavez et al., 2011; Doig and Derreumaux,
2015; Ehrnhoefer et al., 2008; Gavrin et al., 2012; H€ard and
Lendel, 2012; Hawkes et al., 2009; Hayne et al., 2014; Hirohata
et al., 2007; Inbar and Yang, 2006; Jameson et al., 2012; LeVine
et al., 2009; Patel et al., 2015; Prade et al., 2016; Ryan et al., 2012;
Sarkar et al., 2015; Stempler et al., 2011; Woods et al., 2011) and
hence disease (Ahn et al., 2014; Ankarcrona et al., 2016; Flemming,
2014; Hanaki et al., 2016; Jiao et al., 2015; McKoy et al., 2012).
However, we here brieﬂy mention a few well-known molecules to
illustrate how sensitive ﬁbrin ﬁbre morphology can be to their
presence. Various endogenous (inﬂammatory) molecules,
including stress hormones (including the hypothalamic-pituitary-
adrenal axis activity) (Austin et al., 2013; von K€anel, 2015), acti-
vate both the coagulation and ﬁbrinolysis system resulting in net
hypercoagulability. It is also well-known that the inﬂammatory
marker ‘iron’may cause hypercoagulation in iron-overload diseases
(Borgna-Pignatti and Gamberini, 2011; Shah et al., 2015). We have
reviewed in detail the effects of increased (endogenous) ‘iron’,
including its effects on the coagulation system (Kell, 2009; Kell and
Pretorius, 2015b; Pretorius et al., 2013, 2014a; Pretorius and Kell,
2014). Many drugs introduced into the human body are known to
inﬂuence the coagulation system; for a comprehensive list of the
effects of various drugs on coagulation see (Undas and Ari€ens,
2011). The most well-known effect of various drugs on hyper-
coagulation is thrombotic microangiopathy, which is a pathology
that results in thrombosis in capillaries and arterioles, due to an
endothelial injury (Reese et al., 2015; Rosove, 2014). Venous
thromboembolism, is also a well-known result of the use of oral
contraceptives (ESHRE CAPRIWorkshop Group, 2013; O'Brien,
2014).
The above-mentioned molecules and others have direct effects
on the ﬁbrin ﬁbre structure and packaging; these includemolecules
like S-nitrosoglutathione (Bateman et al., 2012), iron and CO
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Nielsen et al., 2015), as well as oestrogen (Swanepoel et al., 2014).
We have shown that addition of unliganded iron salts to ﬁbrinogen,
to healthy plasma, and/or to whole blood, causes pathological ﬁbrin
formation (Lipinski and Pretorius, 2012; Lipinski et al., 2012a,
2012b); however, the addition of various iron chelators to this
plasma (Kell and Pretorius, 2015b; Pretorius et al., 2013) results in a
return of ﬁbrin ﬁbre structure to become similar to that of healthy
ﬁbrin. We also showed that adding chelators to blood/and or
plasma from individuals with iron overload (Bester et al., 2013;
Pretorius et al., 2014a; Pretorius and Kell, 2014) similarly resulted
in the return of the pathologic ﬁbrin structure to that resembling
healthy ﬁbrin packaging. See Fig 10, where Fig 10A shows the ﬁbrin
ﬁbre structure of an individual with hereditary hemochromatosis
and Fig 10 B when the chelators desferal (deferoxamine) is added to
plasma of this patient.
9. Induction of amyloidogenic clotting by added LPS
(endotoxin)
The very potent bacterial inﬂammagen, lipopolysaccharide (LPS)
is well known to cause cytokine activation, and this can cause
hypercoagulation (Chu et al., 2001, 2003); this has been referred to
as endotoxin-mediated hypercoagulation (Slotta et al., 2008). One
mechanism of activation by LPS of the coagulation pathway is via
tissue factor (TF) upregulation (Koch et al., 2009; Monroe and Key,
2007). Previously, it was found that LPS from Escherichia coli
(100 ng mL1) activated the coagulation system when added to
whole blood, via a complement- and CD14-dependent up-
regulation of TF, leading to prothrombin activation and hyper-
coagulation (Landsem et al., 2015). Recently, we also found that
really minute levels of LPS (0.2 ng.L1, representing a molar ratio to
ﬁbrinogen of 1 in 108) might bind directly to circulating plasma
proteins (when added to plasma from healthy individuals), and also
to pure ﬁbrinogen, and that this (rapid) binding might also cause
pathological changes in the coagulation process (Pretorius et al.,
2016b, 2016c). In our hands, the binding was virtually instanta-
neous and we conﬁrmed the direct binding of LPS to pure ﬁbrin-
ogen using isothermal calorimetry. It was clear from thioﬂavin T
measurements that LPS could massively affect the formation of b-
sheets during ﬁbrin packaging. Only a limited number of autocat-
alytic mechanisms can admit this, that whichwe favour (see below)
being essentially a very rapid form of amyloidogenesis and auto-
catalytic structural rearrangement to a b-rich conformation.
10. Anomalous blood clotting involves genuine amyloid
formation
What had been determined earlier, and the same was true forFig. 10. A) Fibrin ﬁbre structure of an individual with hereditary hemochromatosis; B)changes in erythrocyte morphology (Pretorius et al., 2014a, 2016d;
Pretorius and Kell, 2014) and see above, is that small molecules and
the presence of various disease states could havemassive effects on
the morphology of ﬁbrin as judged by (i) its distribution of ﬁbre
diameters and (ii) the formation of what we referred to as ‘dense
matted deposits’, in which the ﬁbres were typically much smaller
than the normal (whose median ~ 85 nm). What we recently
discovered (Pretorius et al., 2016b, 2016c) is that this was actually
accompanied by genuine amyloid formation.
As part of a lengthy series on the role of true dormancy in
bacterial physiology (e.g. (Kaprelyants et al., 1993; Kaprelyants and
Kell, 1992, 1993; Mukamolova et al., 1998, 2002a, 2002b, 2003,
2006; Votyakova et al., 1994)), we have recently come to recog-
nise that a dormant bloodmicrobiome is a signiﬁcant contributor to
a great many chronic, inﬂammatory diseases, not least by shedding
highly inﬂammatory molecules such as lipopolysaccharide (LPS)
(Kell et al., 2015; Kell and Pretorius, 2015a; Potgieter et al., 2015).
This led us to assess (Pretorius et al., 2016b, 2016c) whether LPS had
any effects on blood clotting directly.
As mentioned, it transpired (Pretorius et al., 2016b, 2016c) that
quite miniscule concentrations (amounting to fewer than 1 mole-
cule of freshly added LPS per 108 molecules of ﬁbrinogen!) had a
massive effect on ﬁbrinogen polymerisation to ﬁbrin, including the
production of (in many cases) the thinner ﬁbres and ‘dense matter
deposits’ seen in so many diseases. In particular, the use of the
amyloid-detecting dye thioﬂavine T (Biancalana and Koide, 2010;
Freire et al., 2014; Groenning, 2010; Krebs et al., 2005;
Kuznetsova et al., 2016; LeVine, 1997, 1999; Lindberg et al., 2015;
Picken and Herrera, 2012; Sulatskaya et al., 2011, 2012; Wu et al.,
2009) revealed a massive conversion of ﬁbrin to a b-sheet-rich
form.11. The extent of ampliﬁcation of protein transitions by LPS
can be mimicked by liquid crystals
As phrased by Maji and colleagues (Maji et al., 2009), repeating
motifs can translate a rather non-speciﬁc interaction into a speciﬁc
one through cooperativity. This process can nowadays be observed
directly (Pinotsi et al., 2016), and amounts to potentially quite a
massive ampliﬁcation. In the example of our ownmentioned above
(Pretorius et al., 2016b, 2016c), with LPS freshly added to whole
blood, platelet-poor plasma or ﬁbrinogen solutions, the ratio of
LPS:ﬁbrinogen at which the LPS could induce amyloidogenesis was
~1 in 108; this represents a truly massive ampliﬁcation (see also
(Galant et al., 2016)), and serves to help explain how very small
numbers of bacteria secreting comparatively small amounts of LPS
(albeit of potentially high concentration locally) can exert such a
massive inﬂammagenic effect.
Interestingly, Lin and colleagues also showed that similarly tinywhen desferal (deferoxamine) is added to plasma of this patient. Scale bar: 1 mm.
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cooperative conformation of millions of molecules inmicrodroplets
of nematic liquid crystals ((Lin et al., 2011), and see (Miller and
Abbott, 2013)). The same was true for molecular mimics of LPS
(Carter et al., 2015). Indeed, different liquid crystals can also be used
as ‘biosensors’ (Lowe and Abbott, 2012) to detect b-amyloid for-
mation (Sadati et al., 2015), protein-LPS interactions (Das et al.,
2015) and microvesicles (Tan et al., 2014).
12. Chronic infection and amyloidogenesis
As phrased by Michael Hann (Hann, 2011), ‘unknown knowns’
“… are those things that are known but have become unknown,
either becausewe have never learnt them, or forgotten about them,
or more dangerously chosen to ignore”. Thus, in 1967, Kelenyi could
write “Development of new therapeutical measures in chronic in-
fections has sharply reduced the incidence of secondary amyloid-
osis”. In other words, the fact that chronic infection could induce
amyloidosis was then so well known that it barely merited dis-
cussion! The same is true in comparable works of that era (e.g.
(Hobbs and Morgan, 1963)). Obviously it has since then been
somewhat forgotten, despite the overwhelming evidence (Hill and
Lukiw, 2015; Itzhaki et al., 2016) for a microbial component to AD,
and to amyloidogenesis more generally (Ebert and Nagar, 2008).
Recently (notwithstanding some caveats (Salter et al., 2014)) the
role of dormant or latent microbes in chronic, inﬂammatory dis-
easesmore generally has come to the fore (e.g. (Aagaard et al., 2014;
Domingue, 2010; Domingue and Woody, 1997; Hieken et al., 2016;
Itzhaki et al., 2016; Kell et al., 2015; Kell and Pretorius, 2015a;
Mangin et al., 2014; Mattman, 2001; Nicolson and Haier, 2009,
2010; Potgieter et al., 2015; Proal et al., 2009, 2011, 2013, 2014;
Urbaniak et al., 2014; Woolard and Frelinger, 2008)), and it is
appropriate to recognise this and older literature (e.g. (Billings,
1915; Price, 1923)), some of which is still being rediscovered.
Thus, Chlamydia pneumoniae induces Alzheimer-like amyloid pla-
ques in the brains of BALB/c mice (Little et al., 2004), while amyloid
can also be induced by herpes simplex virus (Wozniak et al., 2007)
and Borrelia (Miklossy, 2008, 2011; Miklossy et al., 2006). In the
present context it is of particular interest that LPS can induce the
conversion of prion protein to its amyloidogenic form (provided the
LPS concentration remains above its critical micelle concentration
(CMC)) (Saleem et al., 2014), and it can do this substoichiometri-
cally. The natural bacterial production of amyloids themselves has
also been reviewed (Blanco et al., 2012; Taylor andMatthews, 2015;
Van Gerven et al., 2015; Zhou et al., 2012).
13. Serum amyloid A
In a similar vein, ‘serum amyloid A’ (Benditt et al., 1971) de-
scribes a heterogeneous family of apolipoproteins (Sipe, 1999) (and
variants (Nedelkov et al., 2005)) that form amyloid ﬁbrils in the
blood, typically in response to inﬂammation or infection (Malle and
De Beer, 1996; R€ocken and Shakespeare, 2002; Sipe, 2000), binding
retinol in the process (Derebe et al., 2014). To this end, this rather
understudied series of proteins may provide very useful bio-
markers for chronic infection/sepsis, for which it is in fact a well-
established (and potent) biomarker (e.g. (Arnon et al., 2007;
Bozinovski et al., 2008; Çetinkaya et al., 2009; Cicarelli et al.,
2008; Derebe et al., 2014; Ebert and Nagar, 2008; Falsey et al.,
2001; Lannergård et al., 2008, 2009; Malle and De Beer, 1996;
Obici et al., 2005; Pizzini et al., 2000; Sipe, 2000; Urieli-Shoval
et al., 2000; Yamada, 1999; Yuan et al., 2013a)). Interestingly, and
in a manner akin to that of prions, it is able to catalyse its own a-to-
b-type conformational transitions (e.g. (Liu et al., 2007; Lundmark
et al., 2002, 2005; Murakami et al., 2015; Murakami et al., 2014;Tasaki et al., 2010; Westermark et al., 2009)), although the ki-
netics are rather sluggish compared to those of blood clotting. In a
similar vein, amyloid deposition in the kidney (Dember, 2006; von
Hutten et al., 2009) may account for the proteinuria seen in dis-
eases such as pre-eclampsia (Kell and Kenny, 2016).
14. Sequelae of amyloidogenesis
While the focus of this review is on amyloidogenesis per se, we
should recognise its sequelae at various levels. Pertinent to the
blood system is the fact that amyloid can induce gross morpho-
logical changes in erythrocytes, leading to their suicidal death
(‘eryptosis’) (Nicolay et al., 2007). Indeed, our own observations
show that major morphological changes in erythrocytes are a
regular accompaniment to the chronic inﬂammatory diseases that
we are discussing (e.g. (Bester et al., 2013, 2015; Pretorius et al.,
2015, 2014a, 2014b; Pretorius and Kell, 2014; Pretorius and
Lipinski, 2013b, 2013c; Pretorius et al., 2016d)), and these
sequelae can include eryptosis (Pretorius et al., 2014c). Eryptosis is
characterized by scrambling of the cell membrane with subsequent
exposure of phosphatidylserine (PS) at the cell surface (e.g. (Lang
et al., 2012; Qadri et al., 2016)), and is essentially a form of
apoptotic cell death (Lang et al., 2015a). Interestingly (and perhaps
surprisingly) this eryptosis involves the cyclin-dependent kinase
CDK4 (Lang et al., 2015b).
As indicated above, many human diseases are known to be
associated with misfolded or amyloid-type proteins (Chiti and
Dobson, 2006; Herczenik and Gebbink, 2008; Knowles et al.,
2014; Moreno-Gonzalez and Soto, 2011; Olanow and Brundin,
2013; Pawlicki et al., 2008; Rambaran and Serpell, 2008; Tipping
et al., 2015;Westermark andWestermark, 2011; Zhang et al., 2014),
and the cytotoxicity of amyloid ﬁbrils is very well established (e.g.
(Ahmed et al., 2010; Airoldi et al., 2011; Bester et al., 2015; Cao et al.,
2013; Fernandez, 2014; Hefti et al., 2013; Kayed et al., 2003; Kayed
and Lasagna-Reeves, 2013; Konarkowska et al., 2006; Liu et al.,
2011; Lorenzo et al., 1994; Marzban et al., 2003; Meier et al., 2006;
Meyer-Luehmann et al., 2008; Minter et al., 2016; Miranda et al.,
2000; Rival et al., 2009; Sengupta et al., 2016)). We note, however,
that although it is the larger ﬁbrils that are observable ultrami-
croscopically, there is evidence that it is the smaller ones that are
the more cytotoxic (Aitken et al., 2010; Baglioni et al., 2006;
Bucciantini et al., 2002; Dobson, 2013; F€andrich, 2012; Glabe,
2006; G€oransson et al., 2012; Haass and Selkoe, 2007; Janson
et al., 1999; Kayed et al., 2003; Konarkowska et al., 2006; Meier
et al., 2006; Pillay and Govender, 2013; Stefani, 2012; Trikha and
Jeremic, 2013; Uversky, 2010; Xue et al., 2009, 2010; Zhang et al.,
2014). As to the mechanism of cytotoxicity, membrane per-
meabilisation (followed by apoptosis) is certainly one (Cao et al.,
2013; Engel et al., 2008; Janson et al., 1999; Nanga et al., 2011).
15. Possible treatments for coagulopathies in the light of
their role in amyloidogenesis
Recognising that ‘dense matted deposits’ are actually amyloid
encourages one to access the literature designed to stop or reverse
amyloidogenesis in other ﬁelds such as Alzheimer's disease (e.g.
(Ahn et al., 2014; Bieschke, 2013; Brumshtein et al., 2015; Cheng
et al., 2012, 2013; Doig and Derreumaux, 2015; Eisele et al., 2015;
Estrada et al., 2006; Flemming, 2014; Hanaki et al., 2016; Hawkes
et al., 2009; Jucker and Walker, 2013; Lopez et al., 2012;
Murakami, 2014; Stamford and Strickland, 2013), and see also
(Cegelski et al., 2009; Cheng et al., 2016; Evans et al., 2015; Klein
and Hultgren, 2015)) or for transthyretin (Ankarcrona et al., 2016;
Galant et al., 2016), and thus it will be of interest to assess candi-
date anti-amyloidogenic molecules in the blood system, where it is
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(see (Kell, 2015; Kell et al., 2011, 2013; Kell and Oliver, 2014)).
In a complementary vein, if (anomalous) ﬁbrin clot formation is
signiﬁcant in AD one might suppose that inhibiting it might be of
value, and it is (Ahn et al., 2014). One might also expect that anti-
coagulant therapies might show beneﬁt, and there are some sig-
niﬁcant hints that this too might indeed be the case (Barber et al.,
2004; Murthy et al., 2009; Ratner et al., 1972; Walsh, 1996; Walsh
et al., 1978), to the extent that this would seem to be well worth
exploring properly. The success of the anticoagulant thrombomo-
dulin in sepsis/septic shock (Eguchi et al., 2014; Hayakawa et al.,
2016; Levi, 2015; Levi and Van Der Poll, 2013b; Mimuro et al.,
2013; Saito et al., 2007; Shirahata et al., 2014; Vincent et al.,
2013; Yamakawa et al., 2015; Yoshimura et al., 2015) also implies
an important role of coagulopathies there.
Since the levels of ﬁbrinogen themselves seem to correlate with
a propensity for AD (see above), and indeed for hypertension
(Bembde, 2012; Haenni and Lithell, 1996; Letcher et al., 1981;
Shankar et al., 2006), lowering them to more appropriate levels
(by means other than by converting them to amyloid forms of
ﬁbrin!) would seem to be a desirable aim in itself.
16. Quo vadis? e systems strategies
We have summarised much of the evidence to the effect that
under some circumstances the ﬁbrin ﬁbres formed by ﬁbrinogen
polymerisation are in fact amyloid in character (Fig 11). This opens
up the ﬁeld to testing this under the many different disease cir-
cumstances where this might be suspected, whether as a diagnostic
or a prognostic. Easy predictions are that the clots seen after stroke
and in any other hypercoagulable conditions will be amyloid and
thus stainable with thioﬂavin T or amyloid-selective dyes (noting
the need for suitable controls and caveats (Coelho-Cerqueira et al.,
2014; Hudson et al., 2009; Wong et al., 2016)). The many estab-
lishedmethods for b-amyloid detection include spectroscopies (e.g.
X-rays (Guilbaud and Saiani, 2011; Sawyer and Gras, 2013; SpencerFig. 11. An elementary systems biology model of how iron dysregulation can stimulate dorm
then trigger inﬂammation, leading to b-amyloid formation in ﬁbrin and ultimately to cell det al., 2015), NMR (Colvin et al., 2015; Karamanos et al., 2015; Su
et al., 2015; Tycko, 2011), mass (Riba et al., 2015; Young et al.,
2014, 2015), circular dichroism (Etienne et al., 2007; Howie and
Brewer, 2009), neutron (Valincius et al., 2008), vibrational (Dasari
et al., 2011; Middleton et al., 2012)) and microscopies (including
appropriate stains (Fig 11 and above)) will be of value in detection.
SEM and TEM (Iadanza et al., 2016) were discussed above, but there
is a clear role too for AFM (Volpatti et al., 2013). Similarly, a plethora
of small molecule studies will clearly be of value in seeking to
modulate such amyloid formation. As is common in modern
biology, strategies for pharmacological inhibition are usually done
piecemeal on the basis of speciﬁc hypotheses about individual
targets. Clearly this must change (Kell, 2013). We have highlighted
several ‘non-traditional’ targets here (e.g. iron metabolism, blood
clotting, ﬁbrinogen-Ab interactions, anti-amyloids) but they have
only been studied singly.
From a network or systems pharmacology perspective (e.g.
(Berger and Iyengar, 2009; Cucurull-Sanchez et al., 2012; Hopkins,
2008;Kell andGoodacre, 2014; vanderGraaf andBenson, 2011)),we
either need polypharmacology (one drug, multiple targets, e.g.
(Achenbach et al., 2011;Anighoro et al., 2014;HuandBajorath, 2010;
Kell, 2013; Kell and Goodacre, 2014; Kell and Oliver, 2014; Mestres
and Gregori-Puigjane, 2009; Peters, 2013; Reddy and Zhang, 2013;
Weinreb et al., 2011, 2012, 2010; Xie et al., 2012). or suitably com-
bined cocktails of individual drugs (e.g. (Borisy et al., 2003; Lehar
et al., 2007, 2008; Small et al., 2011; Zimmermann et al., 2007)).
Armed with these, and based on established mechanisms of action
that involve ﬁbrin(ogen), we may strongly hope to delay the pro-
gression of amyloidogenic diseases in our ageing populations.
In a related vein, we would be remiss not to recognise that an
understanding of how small trigger events can effect massive
conformational changes in designed proteins has potentially
massive beneﬁts for synthetic biotechnology (Currin et al., 2015; Li
et al., 2014), including self-assembling systems (Boothroyd et al.,
2014; Elsawy et al., 2016; Hickling et al., 2014). Nakano and col-
leagues provide a very nice biomaterials example with barnacleant bacterial growth that can in turn lead to antigen production (e.g. of LPS) that can
eath.
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Overall, the crux of the review is that we have indicated that
many more proteins than perhaps currently recognised, and in
particular ﬁbrin(ogen), can form genuine amyloid structures that
are likely to be signiﬁcant in toxicity and disease; clarifying the link
between their essential molecular structure/conformation and
their disease-causing potential is now key, and the ﬁelds of blood
clotting and amloidogenesis can learn much from each other to
mutual advantage.Acknowledgments
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